Objetivo We will exploit the DNA damage response (DDR) to assess and predict individual susceptibility and response focussed on breast cancer and breast cancer therapies. The 1st targeted therapy based on the DDR is inhibition of PARP by olaparib, which induces synthetic lethality in cancer cells with a specific DDR defect. Our members discovered olaparib, which is currently in Phase II trials. Its use in DDR deficient cancers represents a truly personalised healthcare approach. Due to the complexity of the DDR more therapeutically exploitable cases of synthetic lethality are to be discovered, which may be applied to specific tumours and patients. To this end our objectives include: To determine key differences in the DDR between cancer and normal cells, because they constitute important targets for directed individual therapy; establish the roles of DDR mechanisms as these relate to damage induced by anti-cancer therapies to explain inter-individual variation in therapy response; define how different DDR pathways compensate for one another, because this may suggest how targeting one DDR component with a drug could have marked cytotoxic effects on a cancer but not on normal cells; develop and validate markers for functionality of the DDR in fresh tumour biopsies, directly from the clinic, for selection of patients for personalised treatment.Collectively, this consortium has an unrivalled depth and breadth of expertise. We have access to a wide range of new and emerging technologies, while we bring complementary strengths to the project with regard to topics, models, materials, techniques and clinical links, which include the two largest cancer hospitals in Denmark and the Netherlands. Thus, the consortium represents the ‘state-of-the-art’ and has the scope to evolve their knowledge of the DDR into new and exciting areas for assessment of individual susceptibility and prediction of individual responses to cancer therapies, as well as development of new anti-cancer therapies Ámbito científico natural sciencesbiological sciencesgeneticsDNAmedical and health sciencesclinical medicineoncologybreast cancer Programa(s) FP7-HEALTH - Specific Programme "Cooperation": Health Tema(s) HEALTH.2010.2.4.1-8 - Predicting individual response and resistance to cancer therapy. FP7-HEALTH-2010-two-stage Convocatoria de propuestas FP7-HEALTH-2010-two-stage Consulte otros proyectos de esta convocatoria Régimen de financiación CP-FP - Small or medium-scale focused research project Coordinador ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Aportación de la UE € 2 292 900,00 Dirección DR MOLEWATERPLEIN 40 3015 GD Rotterdam Países Bajos Ver en el mapa Región West-Nederland Zuid-Holland Groot-Rijnmond Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Rini De Crom (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (5) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE Reino Unido Aportación de la UE € 685 867,00 Dirección TRINITY LANE THE OLD SCHOOLS CB2 1TN Cambridge Ver en el mapa Región East of England East Anglia Cambridgeshire CC Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Keith Cann (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos KRAEFTENS BEKAEMPELSE Dinamarca Aportación de la UE € 824 750,00 Dirección STRANDBOULEVARDEN 49 2100 Koebenhavn Ver en el mapa Región Danmark Hovedstaden Byen København Tipo de actividad Research Organisations Contacto administrativo Doris Vejby-Soerensen (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos ASTRAZENECA UK LIMITED Reino Unido Aportación de la UE € 685 866,00 Dirección 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS CB2 0AA Cambridge Ver en el mapa Región East of England East Anglia Cambridgeshire CC Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Emma Barton (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos ACADEMISCH ZIEKENHUIS LEIDEN Países Bajos Aportación de la UE € 824 750,00 Dirección ALBINUSDREEF 2 2333 ZA Leiden Ver en el mapa Región West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Liesbeth Dorama (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG Reino Unido Aportación de la UE € 685 867,00 Dirección OLD BROMPTON ROAD 123 SW7 3RP London Ver en el mapa Región London Inner London — West Kensington & Chelsea and Hammersmith & Fulham Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Binoo Rastogi (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos